Tsuji R, Tanaka T, Sohmiya K, Hirota Y, Yoshimoto K, Kinoshita K, Kusaka Y, Kawamura K, Morita H, Abe S
Department of Internal Medicine, Osaka Medical College, Japan.
Int J Cardiol. 1993 Oct 1;41(3):209-17. doi: 10.1016/0167-5273(93)90117-y.
We have previously reported that serum and/or urinary human heart-type cytoplasmic fatty acid-binding protein (HH-FABPc) can be used as an early indicator of myocardial injury (Clin Biochem 1991; 24: 195-201). To confirm the usefulness of HH-FABPc as an early diagnostic indicator of acute myocardial infarction (AMI), its serum and urinary levels were measured in samples obtained within 6 h after the onset of acute coronary syndrome related symptoms. Samples were collected from 97 patients, who were composed of 63 with AMI, 24 with unstable angina and 10 with chest pain syndrome. The positivity of serum and urinary HH-FABPc and cardiac creatine kinase isozyme MB (CK-MB) was analyzed in these samples. Serum HH-FABPc levels in AMI were above normal in 91.4% (64/70) of the samples tested within 3 h of the onset of symptoms and in 100% (111/111) of those tested at 3-6 h. Elevated urinary HH-FABPc levels in AMI were obtained in 88.9% (8/9) of samples at 0-3 h and in 75% (6/8) at 3-6 h. CK-MB activity in AMI was positive in 20% (8/40) and 66.3% (53/80) of serum samples at 0-3 h and 3-6 h, respectively. HH-FABPc was always positive when a serum sample was positive for CK-MB. Serum HH-FABPc at 0-6 h in chest pain syndrome and in unstable angina were positive in 17.8% (5/28) and 56.7% (34/60), respectively. The elevated HH-FABPc in serum and urine was noted much earlier than that of CK-MB during the hyperacute phase of AMI. HH-FABPc showed high positive value in unstable angina, but it was low in normal coronary patients having chest pain. However, HH-FABPc level in unstable angina and chest pain syndrome was lower than that of AMI. Thus, HH-FABPc may be a valuable indicator for the diagnosis of hyperacute myocardial infarction.
我们之前曾报道,血清和/或尿液中的人心脏型细胞质脂肪酸结合蛋白(HH-FABPc)可作为心肌损伤的早期指标(《临床生物化学》1991年;24:195 - 201)。为了证实HH-FABPc作为急性心肌梗死(AMI)早期诊断指标的有效性,在急性冠状动脉综合征相关症状发作后6小时内采集的样本中检测了其血清和尿液水平。样本来自97名患者,其中包括63例AMI患者、24例不稳定型心绞痛患者和10例胸痛综合征患者。对这些样本中的血清和尿液HH-FABPc以及心肌肌酸激酶同工酶MB(CK-MB)的阳性情况进行了分析。症状发作后3小时内检测的样本中,91.4%(64/70)的AMI患者血清HH-FABPc水平高于正常,症状发作3 - 6小时检测的样本中这一比例为100%(111/111)。AMI患者中,0 - 3小时的样本有88.9%(8/9)尿液HH-FABPc水平升高,3 - 6小时的样本有75%(6/8)升高。AMI患者中,0 - 3小时和3 - 6小时的血清样本中CK-MB活性阳性率分别为20%(8/40)和66.3%(53/80)。当血清样本CK-MB呈阳性时,HH-FABPc始终呈阳性。胸痛综合征和不稳定型心绞痛患者0 - 6小时的血清HH-FABPc阳性率分别为17.⑧%(5/28)和56.7%(34/60)。在AMI超急性期,血清和尿液中HH-FABPc升高比CK-MB早得多。HH-FABPc在不稳定型心绞痛中显示出高阳性值,但在有胸痛的正常冠状动脉患者中较低。然而,不稳定型心绞痛和胸痛综合征患者的HH-FABPc水平低于AMI患者。因此,HH-FABPc可能是诊断超急性心肌梗死的一个有价值的指标。